期刊
CHEMISTRY-SWITZERLAND
卷 3, 期 3, 页码 800-817出版社
MDPI
DOI: 10.3390/chemistry3030057
关键词
CORM; gasotransmitters; CO (carbon monoxide); Nrf2; HYCO (hybrid CORMs); heme oxygenase-1; inflammation; metallo-drugs; Nrf2; oxidative stress
资金
- National Institutes of Health [NS095166, NS103036, NS110008, NS116076]
- Department of Defense [AZ180127]
Carbon monoxide, known for its toxicity, has potential therapeutic applications as a gasotransmitter with anti-inflammatory and antioxidant effects. The Nrf2/HO1 pathway is a key target for therapy development due to its role in CO release. Current forms of CO therapy include inhaled CO, carbon monoxide-releasing molecules, and hybrid carbon monoxide-releasing molecules.
Carbon monoxide (CO) has long been known for its toxicity. However, in recent decades, new applications for CO as a therapeutic compound have been proposed, and multiple forms of CO therapy have since been developed and studied. Previous research has found that CO has a role as a gasotransmitter and promotes anti-inflammatory and antioxidant effects, making it an avenue of interest for medicine. Such effects are possible because of the Nrf2/HO1 pathway, which has become a target for therapy development because its activation also leads to CO release. Currently, different forms of treatment involving CO include inhaled CO (iCO), carbon monoxide-releasing molecules (CORMs), and hybrid carbon monoxide-releasing molecules (HYCOs). In this article, we review the progression of CO studies to develop possible therapies, the possible mechanisms involved in the effects of CO, and the current forms of therapy using CO.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据